Navigation Links
Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
Date:2/26/2009

n revenues: - EUR0.3 million corresponding to the initial payment of EUR5.0 million from Pfizer, as a technology exclusivity fee, following the March 2006 agreement that granted Pfizer rights to apply NicOx' proprietary technology in a drug discovery research program covering the field of ophthalmology - EUR2.5 million corresponding to the funding of the research collaboration, pursuant to the above referenced agreement signed with Pfizer in March 2006 - EUR0.6 million corresponding to the balance of the spreading of the initial payment of EUR9.2 million received from Merck following the signature of a collaboration agreement for new antihypertensive drug candidates in March 2006

These amounts initially recorded as prepaid income were deferred over the estimated duration of NicOx' involvement in the research and development programs provided for under the terms of the corresponding agreements. The terms surrounding the duration of NicOx' involvement in these programs are revised periodically, if necessary.

Operating expenses

In 2008, operating expenses amounted to EUR86.4 million, compared to EUR61.8 million in 2007 (adjusted to reflect the reclassification of the research tax credit subsidies into other income as indicated below). During 2008, operating expenses were 87% attributable to research and development expenses and 13% attributable to selling and administrative expenses, compared to 82% and 18% respectively in 2007.

Research and development expenses reached EUR75.0 million in 2008, compared to EUR50.4 million in 2007 (including EUR0.8 million allocated to cost of sales in 2008 and EUR2.2 million in 2007). This significant increase in research and development expenses results mainly from the costs related to the phase 3 development of naproxcinod, such as expenses associated with contract research or
'/>"/>

SOURCE NicOx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
4. American Oriental Bioengineering, Inc. to Report Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
5. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
6. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
7. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
8. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
9. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
10. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
11. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... BOSTON, MA (PRWEB) December 23, 2014 ... generation webinar series is designed to introduce ... and inform users and partners of platform ... features and benefits; empowering users in their ... and powerful tools. , According to SoundConnect’s ...
(Date:12/24/2014)... New York (PRWEB) December 23, 2014 According ... the Long Island Affiliate of ITRA Global, the national office ... but steady recovery. This is evidenced by the third ... strong stock market. Low energy costs have held inflation ... The only negative is the housing market remaining soft. , ...
(Date:12/24/2014)... Nashville, Tenn. (PRWEB) December 23, 2014 ... Hill was elected treasurer for the American Society ... to advancing knowledge and research in reproductive medicine. ... fills a seat on the executive board and will ... , Dr. Hill has actively supported ASRM since ...
(Date:12/24/2014)... San Diego, CA (PRWEB) December 23, 2014 ... Contest where their Twitter followers can submit their ... for themselves and their lab mates. , For those ... beloved lab mates, the Pipette.com Holiday in the Lab ... encourages Pipette.com Twitter followers to send pictures ...
Breaking Biology Technology:SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2
... CHERTSEY, England, Dec. 27, 2011  United Therapeutics Corporation ... subsidiary, United Therapeutics Europe, Ltd., announced today that ... Securite Sanitaire des Produits de Sante (AFSSAPS) ... the treatment of pulmonary arterial hypertension (PAH).  Remodulin ...
... WEST LAFAYETTE, Ind. Researchers have shown ... manipulate light in new ways that could make possible a ... and computers., The researchers ... property of light called its phase. Light is transmitted as ...
... 2011 In recognition of the International Year of Chemistry ... The Changing Role of Chemistry in Drug Discovery . ... with insights from industry experts, the new report forecasts the ... report suggests, a much more targeted, patient-specific approach will define ...
Cached Biology Technology:Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union 2Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union 3Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union 4Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union 5'Nanoantennas' show promise in optical innovations 2'Nanoantennas' show promise in optical innovations 3Thomson Reuters Research Forecasts the Onset of the Targeted Drug Discovery Era 2Thomson Reuters Research Forecasts the Onset of the Targeted Drug Discovery Era 3
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
(Date:12/17/2014)... -- Automation is fundamentally transforming the travel experience and ... borders. Over the past decade, ePassports, biometric readers, ... to self process through border control via eGates ... increasing number of airports, seaports, and land borders ... Maxine Most , Principal at Acuity Market ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... crystallised a protein that may help gut bacteria bind to the ... identify strains that are likely to be of real benefit to ... to have a beneficial effect, and if they attach to surfaces ... enough to exert their activity," says Dr Nathalie Juge from the ...
... College of Medical Toxicology (ACMT) have signed an agreement to ... Toxicology (JMT), the official journal of the ACMT, beginning ... University of Pennsylvania Press. The Journal of ... advancing the science and practice of medical toxicology. The ...
... food is a matter of debate. A high-profile study a ... of their carbon from trees and leaves, evidence for a ... But new research from the University of Washington shows this ... richer diet for fish and other aquatic life, according to ...
Cached Biology News:A sticky solution for identifying effective probiotics 2Springer and the American College of Medical Toxicology to work together 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3
... is the cycler that revolutionized thermal ... and swappable blocks ensure consistent results, ... rugged machine is more than just ... new features and upgrades as research ...
Request Info...
Peroxidase Protective Buffer is a diluent formulated to stabilize the activity of Chemicon horseradish peroxidase (HRP)-antibody conjugates at high conjugate dilution for extended periods....
... Soybean-Casein Digest Medium (TSB), USP is a ... for general laboratory use. Due to the ... the medium will support growth of many ... etc. , Product conforms to United States ...
Biology Products: